From Clinical Insight to Trial Design: Advancing Circulating Tumor DNA-Informed Care in Pancreatic Cancer

Ascherman B, King D. J Gastrointest Oncol 2026

Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma

Ansstas G., Khaddour K., Sudhaman S., et al. CCR. 2026

Circulating tumor DNA refines risk stratification of neoadjuvant therapyresistant breast tumors

Magbanua M. J. et al; Nature Communications 2025

Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study

Nakamura Y. Reiter J.G. Natarajan P. et al. npj Precis. Onc. 2026

Circulating tumor DNA refines risk stratification of neoadjuvant therapy- resistant breast tumors

Mark Jesus M. Magbanua, et al. Nature Communications 2025

Genetic Testing in the Management of Adult CKD

Chebib, F; et al. Journal of the American Society of Nephrology 2025

ctDNA Monitoring in Ovarian Cancer Patients Receiving PARPi

Toboni, Michael D, et al. Gynecologic Oncology 204 (2026)

Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1

Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer

Ketch et al. JCO PO 2025

Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients With Resected Stages I to III Colon Ca

Cohen et al. Annals of Surgery 2025

Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Ca

Abdelrahim M, et al. JCO Preci Oncol. 2025

Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcin

Zaanan et al. Nat Commun, 2025

A Two-Threshold Algorithm using Donor-derived Cell-free DNA Fraction and Quantity to Detect Acute Rejection After Heart Transplantation

Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort

Gilstrop Thompson, et al. OBSTETRICS & GYNECOLOGY 2024

Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

Narkhede M, Tomassetti S, Iqbal M. Front. in Oncol 2024

Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer

Martin T, Dinerman A, Sudhaman S, et al. J Thorac Cardiovasc Surg. 2024

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Lele SJ, Adilbay D, Lewis E, et al. Otolaryngology–Head and Neck Surgery. 2024

Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma

Correa AF, Kalashnikova E, Wu H-T, et al. Oncologist

Genetics of Chronic Kidney Disease

Vivante, Asaf; NEJM 2024